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Objective: The aim of this study was to preliminarily evaluate the efﬁcacy and outcomes of injectable
genetically engineered chondrocytes virally transduced with TGF-b1 (GEC-TGF-b1) compared to placebo.
Design: A multi-center, double-blinded, placebo-controlled, randomized study of adults with knee
osteoarthritis. A total of 102 patients were 2:1 randomized to GEC-TGF-b1 or placebo. Primary outcomes
assessed were (1) function of the knee joint, scored using the International Knee Documentation
Committee (IKDC); and (2) pain, measured by Visual Analog Scale (VAS). Secondary endpoints assessed
were pain and analgesic use, quality of life (QOL), and adverse events (AEs) including need for total knee
arthroplasty after treatment.
Results: IKDC showed signiﬁcant improvement in the GEC-TGF-b1 group over the placebo at week 12
(least mean square difference (LSMD): 10.3; P ¼ 0.0342), week 52 (LSMD: 13.6; P ¼ 0.0082), and overall
(LSMD: 8.6; P ¼ 0.0453). VAS Analysis showed a signiﬁcant improvement in GEC-TGF-b1 group
compared to placebo at weeks 12 (LSMD: 13.8; P ¼ 0.0162), 52 (LSMD: 13.1; P ¼ 0.0332), and overall
(LSMD: 10.1; P ¼ 0.0350). Reduction in pain severity at week 12 and 52, frequency at 24 h and week 52,
and the percentage of patients in the GEC-TGF-b1 group receiving analgesics at week 4 (27 vs 40%) and
12 (27 vs 37%) was observed.
Conclusions: GEC-TGF-b1 patients had more positive responses on the IKDC, VAS, and were less likely to
require analgesics.
Trial Number: ClinicalTrials.gov (NCT01221441) e “Study of TG-C in Patients with Grade 3 Degenerative
Joint Disease of the Knee”.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Articular cartilage damage leads to osteoarthritis, which ul-
timately results in decreased quality of life and marked disability,
pain, and functional limitations1. As population size, obesity rate,
and life expectancy all increase, the incidence of knee.A. Mont, Rubin Institute for Adva
D 21215, USA. Tel: 1-410-601-850
ondamont@aol.com (M.A. Mont).
ternational. Published by Elsevier Losteoarthritis will continue to rise2,3. Therefore, more patients
will need joint arthroplasty. Despite prosthetic survivorship
>15e20 years for total knee arthroplasty, younger patients may
require additional surgery. It is therefore paramount that alter-
native treatments are developed to delay arthroplasty as long as
possible4,5.nced Orthopaedics, Center for Joint Preservation and Replacement, Sinai Hospital of
0; Fax: 1-410-601-8501.
td. All rights reserved.
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thus, injuries lead to progressive, permanent damage6e8. Presently,
standard non-operative treatment for knee osteoarthritis consists
of several options, which may help alleviate disease symptoms, but
do not restore damaged cartilage9e11. However, recently, an
exploration of novel techniques of cell-mediated cytokine gene
therapy for cartilage regeneration, including the use of various
growth factors and bone morphogenetic proteins. Speciﬁcally, TGF-
b proteins induce osteogenesis and chondrogenesis, and play a role
in cell growth, differentiation, and extracellular matrix protein
synthesis12. Moreover, studies suggest that TGF-b stimulates pro-
teoglycan synthesis and chondrocyte proliferation, and may also
possess anti-inﬂammatory and immunosuppressive properties13.
One novel technique involves human chondrocytes transduced
with a viral vector containing the gene for TGF-b1 transcription.
This study preliminarily evaluated injectable genetically engi-
neered allogeneic human chondrocytes expressing TGF-b1 (GEC-
TGF-b1) compared to placebo in patients with grade 3 degenerative
knee disease. Primary outcomes assessed efﬁcacy with regards to
knee functionality and symptoms of knee osteoarthritis pain, as
well as safety of administration by observation of adverse events
(AEs), ﬁndings and laboratory tests, including immune analyses.
Secondary endpoints evaluated include incidence and analgesia
dose and/or anti-inﬂammatory medications; cells expression
outside the injection site; and efﬁcacy of GEC-TGF-b1 by evaluating
the need for secondary procedures.Methods
Patient selection
This is the 1 year follow-up of a 2 year 2:1 ratio multi-center,
double-blinded, placebo-controlled, randomized study of 102
adults with KellgreneLawrence grade III knee osteoarthritis. All
institutions obtained institutional review board approval, and the
study was registered in ClinicalTrials.gov (NCT01221441) as “Study
of TG-C in Patients with Grade 3 Degenerative Joint Disease of the
Knee”. It was conducted in accordance with the International
Conference on Harmonization Tripartite Guideline, Guideline for
Good Clinical Practice, ethical principles with origin in the Decla-
ration of Helsinki, as well as the USA Code of Federal Regulations.
Patients were included if all inclusion criteria were met. These
were: age between 18 and 70 years; body mass index (BMI) be-
tween ‘18.5 and 45.5’ kg/m2; grade 3 radiographic knee osteoar-
thritis as determined by the criteria of KellgreneLawrence; pain
symptoms for more than 4 consecutive months. Please see
Appendix A for complete list of inclusion and exclusion criteria.Table I
Demographics
Parameter Statistic Treatment (N ¼ 67) Placebo (N ¼ 35)
Age (years) Mean (range) 56.7 (34e71) 56.4 (25e70)
Sex Female 43 21
Male 24 14
Race Caucasian/White 53 29
Black 12 4
Hispanic 2 2
Body mass
index (kg/m2)
Mean (range) 29.6 (19e43) 29.6 (20e43)Patients
Patients (n ¼ 102) were randomized to receive genetically
engineered chondrocytes virally transduced with TGF-b1 (GEC-
TGF-b1) (TissueGene-C; TissueGene Inc., Rockville, Maryland, USA
(n ¼ 67)), or placebo (2 ml normal saline (0.9%); n ¼ 35) according
to a randomization list managed by Comprehensive NeuroScience
Inc., (CNS; Morrisville, North Carolina). Each site was provided with
a randomization list managed by an unblinded pharmacist or lab
technician. As patients were screened and prepared for enrollment,
the unblinded pharmacist referred to the randomization list and
completed the Investigational Product Request Form. TissueGene,
Inc. shipped cells to the unblinded pharmacist at the site or placebo
was prepared by the unblinded pharmacist. All injections were
sequentially numbered to ensure standardization, and adminis-
tered by the principal investigators, who were blinded to injectiontype. Follow-up evaluations were conducted by blinded clinicians,
unaware of study group.
The study was initiated in May 2011 and concluded October
2013 once patient enrollment numbers were met. The GEC-TGF-
b1cohort consisted of 67 patients (24men and 43women) who had
a mean age of 57 years (range, 34e70), and BMI of 30 kg/m2 (range,
19e43). The placebo cohort consisted of 35 patients (14men and 21
women) who had amean age of 56 years (range, 25e70) and BMI of
30 kg/m2 (range, 20e43) (Table I). Therewere 17 (25.4%) patients in
the treatment arm and nine patients (25.7%) in the control group
who discontinued the study prematurely (See Consort Flow for
patient allocation). The ratio of treatment to placebo in the with-
drawn patient population is approximately 2:1 (same ratio for
entire study). After excluding 26 individuals who did not complete
the trial, 76 were randomized to GEC-TGF-b1 treatment group
(n ¼ 50) or the placebo group (n ¼ 26) (Fig. 1).
Determination of sample size
The sample size was based on the assumption that the standard
deviation for International Knee Documentation Committee (IKDC)
Subjective Knee Evaluation is between 20 and 25 points and that
the correlation between baseline and month 6 assessment is at
least 0.5. A 2:1 ratio of TissueGene-C (TG-C) patients to control
(67 TG-C and 33 control) is needed at least a 12.1e15.1 point dif-
ference from the control group (for SD ¼ 20 and 25, respectively)
with alpha¼ 0.05 and 80% power. This sample size allows detection
of an 0.6 effect size for Visual Analog Scale (VAS), with alpha¼ 0.05
and 80% power.
Treatment
GEC-TGF-b1 is a 3:1 mixture of non-transduced allogeneic hu-
man chondrocytes and transduced allogeneic human chondrocytes
expressing TGF-b1, irradiated during manufacturing to render
replication incompetent. The GEC-TGF-b1 chondrocytes were
derived from a single human donor, grown from cartilage tissue
from an infant polydactyly ﬁnger. Testing for viruses absence and
other adventitious donor agents and the cell line were conducted.
Chondrocytes virally transduced with TGF-b1 represent a cell-
mediated cytokine gene therapy approach designed for local
intra-articular administration in patients who had osteoarthritis to
stimulate cartilage regeneration via cytokine gene expression, TGF-
b1, via a retroviral vector.
Patient's knee joints were aspirated to remove synovial ﬂuid
prior to GEC-TGF-b1 or placebo administration. Treatment or pla-
cebo (2 ml normal saline (0.9%)) was injected via 18 gauge needle
using the inferolateral or inferomedial entry point with the knee in
90 ﬂexion. Synovial ﬂuid aspirated was analyzed to rule out
infection. To avoid cell shearing, injection was performed over
approximately 10 s. Both patient and physicians were blinded at the
time of injection.
Fig. 1. Enrollment ﬂowchart.
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Patients underwent examination of endpoints at screening,
baseline, 24 h post-dose, week 4, and months 3, 6, and 12, except
Short-Form 36, which was assessed at baseline and months 6 and
12. Patients had a physical examination at screening, prior to
dosing, 24 h after dosing, and at all study visits. A drug screen,
hepatitis B virus (HBV)/hepatitis C virus (HCV) test, and human
immunodeﬁciency virus (HIV) I/II test were performed at
screening. Abnormalities observed during physical and laboratory
examinations were recorded.
The primary efﬁcacy endpoints assessed symptomatic
improvement, speciﬁcally: (1) function of the knee using the
IKDC subjective knee evaluation; and (2) pain measured by a
100 mm VAS. Secondary endpoints included assessment of symp-
toms, pain, and functionality using the Knee Injury and Osteoar-
thritis Outcome Score (KOOS), the Lysholm Knee Scale, and the
Lower Extremity Functional Scale (LEFS), as well as incidence of
AEs, use of analgesic medications, and need for subsequent surgery.
The IKDC Knee Examination Form was used at each visit14,15. To
evaluate limitations associated with knee osteoarthritis, patients
completed the KOOS16,17 at all time points. The KOOS is subdivided
into ﬁve subscales (symptoms, pain, function in daily living (ac-
tivities of daily living e ADL), sports ability, and quality of life
(QOL)), and each subscale is reported separately (range 0e100points). Patients were evaluated according to the LEFS18,19, Lysholm,
and SF-36 questionnaires20. The LEFS is a patient-rated evaluation
of ability to perform activities-of-daily-living. The Lysholm Score
(0e100 points) queries related to locking, pain, and the effects of
injury on knee-related activities. The SF-36 is a general, valid, and
reliable multipurpose health survey that assess functional health
and well-being, through mental and physical components
evaluations.
Reduction in pain was measured by 100-mm VAS, pain ques-
tionnaires, KOOS subscores, and frequencies/doses of analgesics.
The pain questionnaire describes severity, frequency, and the time
and speed of pain onset.
To further assess any improvements in VAS or IKDC in with-
drawn patients, they were analyzed for modiﬁed OMERACT-OARSI
response21. A positive response is deﬁned as either: (1) high pain
improvement (VAS) or function (IKDC) 50% and absolute score
changes 20, or; (2) moderate improvements in pain and function
20% and absolute score changes 10 for both VAS and IKDC.
Untoward medical occurrences were recorded even if not
necessarily causally-related with treatment. AEs can be any unfa-
vorable and unintended sign (including abnormal laboratory ﬁnd-
ings), symptoms, or disease temporally associated with use of an
investigational product, whether or not related. Blood samples
were analyzed for TGF-b1 expression by enzyme-linked immuno-
sorbent assay (ELISA) and by polymerase chain reaction (PCR) for
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tibodies to HLA-A, B, and C, antibodies to TGF-b1, C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), and multiplex cyto-
kine analyses were performed to observe for any allogeneic re-
sponses. Patients could undergo knee arthroplasty at any time.
Statistical analysis
Endpoint analyses were performed using repeated measures
and mixed-model methodology. A linear mixed-model was used
for IKDC or VAS with change from baseline as the dependent var-
iable and post-treatment time point (weeks 4, 12, 24, and 52) and
treatment, as well as interactions between time point and treat-
ment as ﬁxed factors and with subject included in the model as a
random factor. A spatial power covariance structure for unequally
spaced time intervals was used to model the repeated assessment
over time. Denominator degrees of freedom were adjusted using
KenwardeRoger's method. Treatment comparisons were made at
each time point, with the primary comparison at week 52, and
overall across all four time points. Each parameter was analyzed
with linear mixed-model repeated measures. Comparisons at each
time point were performed by contrasts within a single model.
Results
Primary endpoint
Knee evaluations and pain
The change from baseline IKDC showed a signiﬁcant improve-
ment in the least square (LS) mean of GEC-TGF-b1 group compared
to placebo at week 12 (least mean square difference (LSMD [95%
CI]: 10.3 [0.8e19.9]; P ¼ 0.0342), week 52 (LSMD [95% CI]: 13.6
[3.6e23.6]; P ¼ 0.0082), and overall (LSMD [95% CI]: 8.6 [0.2e17.0];
P ¼ 0.0453). The LSMD at week 4 and 24 between the GEC-TGF-b1
and placebo were not statistically signiﬁcant (Table II and Fig. 2).
Analysis of VAS showed a signiﬁcant improvement in the GEC-
TGF-b1 group compared to placebo at week 12 (LSMD [95%
CI]:13.8 [25.0e2.6]; P¼ 0.0162), week 52 (LSMD [95% CI]:13.1
[25.1e1.1]; P ¼ 0.0332), and overall (LSMD [95% CI]: 10.1
[19.4e0.7]; P ¼ 0.0350). While the LS mean differences in VAS
between the GEC-TGF-b1 and placebo at week 4 and 24 were not
statistically signiﬁcant, there was a trend towards improvement
(5.8 [16.7e5.20; P ¼ 0.2991 and 7.7 [19.0e3.7]; P ¼ 0.1832],
respectively) (Table III and Fig. 3).
Results from modiﬁed OMERACT-OARSI indicated for the with-
drawn patients, the response rate was 58.3% for GEC-TGF-b1 group
and 42.9% for placebo (lower than overall response rate). However,
most patients withdrew on, or before 24 weeks; efﬁcacy was
observed to be higher in the remaining patients at later time points
(week 24 and 52). Ten (10) withdrawn patients had improvements
in pain and/or function that correlated to a positive response ac-
cording to modiﬁed OMERACT-OARSI criteria, whereas, 16 patients
did not. Patients who withdrew did not respond as well as the
overall patient population.Table II
Summary of IKDC outcomes
Visit TissueGene-C Placebo
LS mean LS mean LS mea
Week 4 13.8 11.2 2.6
Week 12 23.0 12.7 10.3
Week 24 20.4 12.5 7.9
Week 52 23.3 9.7 13.6
Overall 20.1 11.5 8.6The Lysholm, KOOS, and LEFS, did not demonstrate signiﬁcant
differences between the treatment and placebo at a majority of
times (P > 0.05; Table III for values). However, evaluation of sub-
jective knee functionality demonstrated that LSMD (95% CI)
signiﬁcantly improved from baseline for KOOS Pain between GEC-
TGF-b1 and placebo (9.4 (0.4e18.4) at week 52 P ¼ 0.0416). The
LSMD (95% CI) between the GEC-TGF-b1 group and placebo for
Lysholm at week 52 approached signiﬁcance (P ¼ 0.0723)
(Appendix B).
AEs
Through 1 year in the GEC-TGF-b1 cohort, 58 of 67 patients
(87%) experienced AEs. Most were mild (13%) or moderate (67%),
with severe AEs occurring in 10%. In the placebo group, 27 of 35
(77%) patients reported AEs. The majority were mild (26%) or
moderate (43%) in severity, with 9% being severe. In the study
cohort, 45 patients (67%) were experiencing AEs related to study
drug. A majority occurred within the ﬁrst 4 weeks post-treatment
administration, with 53 (79%) occurring in the GEC-TGF-b1cohort,
while the placebo cohort had 18 (51%) events. Forty-one patients
(61%) in the GEC-TGF-b1 cohort had an event after 4 weeks, while
21 (60%) of the placebo patients had events in the same period. Of
53 events in the GEC-TGF-b1cohort, 44 were considered possible,
probably, or deﬁnitely related to the drug, while 9 of 41 events were
considered to be related after 4 weeks. In the placebo cohort, 8 of 18
events were considered possible, probably, or deﬁnitely related to
the placebo, while 1 of 21 were related to the placebo treatment.
The most common AEs deﬁnitely related to treatment with GEC-
TGF-b1 were joint inﬂammation (19 patients), arthralgia (14 pa-
tients), and effusion (14 patients). Three serious AEs were experi-
enced, one GEC-TGF-b1 and two placebo patients. These serious
adverse events (SAEs) were not considered related to study medi-
cation. No patients were withdrawn from the study due to an AE.
No SAEs were reported for abnormal laboratory values. No signiﬁ-
cant trends were seen with respect to immunologic responses to
GEC-TGF-b1. The AEs of increased C-reactive protein and increased
numbers of eosinophils were seen in one GEC-TGF-b1 and no pla-
cebo patients. Increased interleukin or cytokine values were re-
ported as AEs in six GEC-TGF-b1 and one placebo patient.
Development or increase in TGF-b1 antibodies was not a signiﬁcant
clinical or efﬁcacy concern in patients receiving GEC-TGF-b1. Anti-
body analysis indicates that there were no increases in antibodies
to donor-speciﬁc HLA antigens.
Secondary endpoints
Pain questionnaire and analgesic medication
At week 12 and 52 visits, the mean pain difference signiﬁcantly
improved from baseline in treatment group compared to the pla-
cebo group 0.91 vs 0.42 and 8.6 vs 0.30 (P ¼ 0.0184 and
0.0399). At the week 52 time point, the mean (SD) change from
baseline for frequency of pain was 1.14 (1.175) and 0.35 (1.089)
in the treatment group and placebo groups (P ¼ 0.0248). There
were no statistically signiﬁcant differences between treatment and95% CI of LS mean difference P-value
n difference
6.8e12.0 0.5846
0.8e19.9 0.0342
1.8e17.6 0.1089
3.6e23.6 0.0082
0.2e17.0 0.0453
Fig. 2. Mean IKDC subjective knee evaluation scores over time by treatment group.
Table III
Summary of VAS outcomes
Visit TissueGene-C Placebo 95% CI of LS mean difference P-value
LS mean LS mean LS mean difference
Week 4 26.9 21.1 5.8 16.7e5.2 0.2991
Week 12 37.2 23.4 13.8 25.0e2.6 0.0164
Week 24 35.5 27.8 7.7 19.0e3.7 0.1832
Week 52 39.9 26.9 13.1 25.1e1.1 0.0332
Overall 34.9 24.8 10.1 19.4e0.7 0.0350
Fig. 3. Mean VAS pain scores over time by treatment group.
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and severity and frequency of pain at remaining time points
(Appendix B). We demonstrated that patients in the treatment
group required less pain medication at week 4 and 12 compared to
the placebo cohort (27 vs 40% and 27 vs 37 %), however, at
remaining time points, analgesic use was similar (Table IV).
QOL assessment
The LSmean difference (95% CI) between treatment and placebo
groups for overall SF-36 domain score was 0.5 (4.2 to 5.2) at week
24, 0.4 (5.4 to 4.6) at week 52, and 0.1 (4.1 to 4.3) overall
(P ¼ 0.837, 0.879, and 0.981).
Expression of GEC-TGF-b1 outside of knee
One patient at 12 weeks in the GEC-TGF-b1 group and one pa-
tient at 24 weeks in the placebo group had an “indeterminate”
value for the presence of replication competent retroviruses. All
other assays were rated as “not detected” or were not performed.
Secondary procedures
One subject had arthroscopy on their treated knee. One placebo
patient had bilateral total knee arthroplasty (TKA) after week 4 and
was discontinued from the study, whereas, no patients in the GEC-
TGF-b1 cohort underwent TKA.
Discussion
This study described the use of a novel injectable allogeneic
human chondrocytes expressing TGF-b1 in patients with grade 3
chronic degenerative knee disease. We found that patients
receiving GEC-TGF-b1 had a more positive response in IKDC
evaluation, pain rated by VAS, and pain questionnaires, and were
less likely to require analgesics compared to placebo. GEC-TGF-b1
appears to improve symptoms and pain related to knee
osteoarthritis.
The potential positive effects of injectable retroviral transduced
allogeneic human chondrocytes expressing TGF-b1 were ﬁrst
described by Noh et al.22, who conducted a pre-clinical evaluation
of cartilage in animal models involving induced knee articular
damage. Articular defect examination demonstrated signs of
regeneration at autopsy. At 8 weeks, biopsy ﬁndings suggested that
TG-C resulted in proliferative foci of new chondrocytes in hyaline
cartilage matrix in both rabbits and goats, and these were made up
of young chondrocytes in hyaline matrix, which stained positive
with toluidine blue and type II collagen. Human chondrocytes
(TGF-b1) staining revealed involvement of small foci only at defect
site, but not in other joint areas. The defect foci morphology andTable IV
Summary of patients taking analgesia medication
TissueGene % Placebo %
Patients taking Analgesia Medication at:
Screening 19.4 25.7
Baseline 22.4 25.7
24 h 20.9 17.1
Week 4 26.9 40.0
Week 12 26.9 37.1
Week 24 29.9 28.6
Week 52 31.3 28.6staining characteristics indicated hyaline cartilage consistent with
articular cartilagewas present. At 1 year, therewas positive staining
of the proliferating cartilage in ﬁve of eight animals, indicated
production of type II collagen. The authors concluded that TG-C
may potentially be an effective strategy to promote cartilage
growth, type II collagen deposition, and hyaline cartilage formation
for articular defects.
Following this initial pre-clinical study, Ha et al.23 performed the
ﬁrst phase I trials in humans, evaluating safety and biologic activity
of injectable TG-C in 12 knees. No severe AEs related to the TG-C
treatment were noted, with the most common AEs being effu-
sion, which resolved in all cases. This injectable TG-C, led to 10 of 12
patients showing improvements in Knee Society Clinical Ratings
from baseline at 6 months, with trending improvements in range-
of-motion and pain up to 1 year following dosing. Patients
demonstrated marked improvements (>40%) in pain scores (VAS)
for up to 3 months following dosing. These authors concluded that
there were minimal localized AEs and that there may be a trend
towards improvement in knee osteoarthritis symptoms. The ﬁnd-
ings of the present study are in concordance with this phase I trial,
demonstrating that TG-C may be a beneﬁcial treatment option, will
the majority of AEs being effusion or inﬂammation which was self-
limiting.
This study has shown that GEC-TGF-b1 was safe and generally
well-tolerated. There were a greater proportion of patients in the
GEC-TGF-b1 cohort that exhibited AEs, but most were classiﬁed as
mild or moderate severity. The majority of GEC-TGF-b1 patients
exhibited knee inﬂammation, which was related to the treatment.
These events are local reactions that occurred shortly after
administration and were not late-onset AEs due to drug or pro-
gression of disease. It is hypothesized that TGF-B1 in GEC-TGF-b1
may induce an inﬂammatory response. Animal studies have pre-
viously indicated that TGF-B1 produced by the transduced cells
may induce an inﬂammatory response, however, these effects
were transient and reversible. These results are consistent with
the potential effects of TGF-B1. We also noted that the inﬂam-
mation seen is not unexpected based on animal safety studies:
acute toxicity studies indicated GEC-TGF-b1 may induce local
inﬂammation as evidenced by mild-to-moderate synovial cell
hyperplasia, synovial, vascularization, and pannus formation when
injected intra-articularly in rabbits and edema, nodules, and
chronic inﬂammation at the subcutaneous injection site and/or
skin/subcutis when injected subcutaneously in mice. These ﬁnd-
ings were transient and were not unexpected due to the fact that
th0e cells administered were xenogeneic and the TGF-b1 protein is
known to induce synovial proliferation and inﬂammation. To avoid
this, this novel technique irradiates the transduced cells prior to
dosing to render their replication incompetent, which allows cells
to express TGF-b1 for up to 2 weeks. This allows for action on
normal human chondrocytes, while ensuring no prolonged or
excessive TGF-b1 expression and that gene-modiﬁed cells do not
persist in vivo.
Despite this study being a prospective, multi-center, double-
blinded, placebo-controlled, randomized trial, there were several
limitations. The cohort size was somewhat small, and a relatively
large number of patients dropped out. Our evaluation only
extended to 52 weeks, thus it is difﬁcult to assess the longer-term
efﬁcacy of this treatment option. However, we plan to further
follow these patients to evaluate long-term efﬁcacy and safety.
Furthermore, several endpoints were deﬁned as primary outcomes,
which may result in multiplicity issues. As a result, this may lead to
an increased rate of false positive conclusions, such as claims for the
effectiveness of a treatment. To address this, we have limited our
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analyses were performed and declared the secondary variables as
supportive, although we acknowledge that multiplicity may still be
present. Also, our inclusion criteria included an extensive age range
as well as patients who may have had undiagnosed concomitant
hip osteoarthritis. We did not want to exclude any patients above
18 years of agewith signs of osteoarthritis, and this may add bias, as
the population is not homogenous. Furthermore, to the best of our
knowledge the primary area of painful arthritis would have been
the knee, however, there is a potential bias for unknown hip dis-
ease, but we believe that these ﬁndings would have had equal
distributions in both cohorts. Our purpose was to assess the effect
of this injection, compared to patients who would have undergone
no treatment at all in a clinical setting. Thus, we believe that the use
of normal saline was the appropriate injection to emulate ‘no
treatment’, as providing no injection at all would compromise the
blinding in this study. Saline has also been used in several
randomized-controlled studies22,24e26. Furthermore, several
studies, such as that by Noh et al. demonstrated no cartilage growth
with chondrocytes alone, though this was in animal studies and as
such, was the basis of our decision to compare GEC-TGF-b1 to
placebo. However, we do appreciate that further comparisons to
chondrocyte injections alone may be important, and thus future
studies should evaluate this. Furthermore, detection of TGF-b in
synovial ﬂuid was not included in the study protocol or in the
endpoints assessed, and incorporating this in future analyses may
be beneﬁcial.
We have seen various levels of cartilage improvement in the
treatment group compared to the control, and preliminary
analysis of radiographic data have demonstrated that the treat-
ment injection had beneﬁcial effects on hyaline cartilage regen-
eration. However, full radiographic analysis includes assessment
of: (1) cartilage morphology; (2) cartilage lesions; (3) bone
marrow lesions; (4) subchondral cysts; (5) osteophytes; (6) bone
attrition; (7) effusions; and (8) synovitis as determined by 3T
magnetic resonance imaging (MRI). Such extensive evaluations of
all the patients are still under analysis, and radiographic as-
sessments of cartilage growth will be incorporated in a future,
follow-up study.
Currently, there are various options and surgical procedures to
relieve the symptoms associated with knee osteoarthritis, how-
ever, these routes only manage symptoms, and in the case of
surgery, may increase patient morbidity. One of the major limi-
tations in knee osteoarthritis treatment is the lack of any inter-
vention proven to directly impact the disease process and possibly
reverse the current knee damage. Moreover, recent exploration
into novel techniques of cell-mediated cytokine gene therapy and
tissue engineering approaches for cartilage regeneration has been
shown to have a promising future in knee osteoarthritis treat-
ment22,23,27. Our study demonstrated that GEC-TGF-b1 may have
positive effects on pain levels in patients who have knee osteo-
arthritis, as demonstrated by the VAS and IKDC scores, at 1 year
follow-up when compared to the control cohort. Patients
receiving GEC-TGF-b1 had more positive responses on the knee
evaluation and pain, and they were less likely to require analgesics
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 Ages of 18e70 years
 General good health
 Physical examination
 Normal hematology
 Serum chemistry
 Urinalysis screening a
 Negative history of signiﬁcant organ system disorders
 Body mass index (BMI) between ‘18.5 and 45.5’ kg/m2
 Blood pressure measurements
 Systolic blood pressure between 90 and 160 mmHg and
 Diastolic blood pressure between 50 and 90 mmHg)
 KellgreneLawrence grade 3 chronic OA of the knee
 Symptoms of pain for more than 4 consecutive months
and a intensity of 40 and 90 on the 100-mm scale
 Cleared for use protocol speciﬁed equipment (3T MRI)
 Provided written informed consent after the nature of the
study is fully explained and understood by the patient
 71 years of age or older
 Abnormal hematology, serum chemistry, or urinalysis screening laboratory values
 Taken non-steroidal anti-inﬂammatory drugs (NSAIDs) within 14 days of baseline visit
 Taken steroidal anti-inﬂammatory medications within 2 months of baseline visit
 A recent (within 1 year) history of drug abuse and/or a positive urine drug test at the time
of screening
 Received injections to the treated knee within 2 months prior to study entry
 Contraindications for 3T MRI
 Pregnant or currently breast-feeding children
 History of systemic, rheumatic or inﬂammatory disease of the knee or chondrocalcinosis,
hemochromatosis, inﬂammatory arthritis, osteonecrosis of the femoral condyle, arthropathy
of the knee associated with juxta-articular, Paget's disease of the femur or tibia, ochronosis,
hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, synovial
chondromatosis, and/or history of inﬂammatory arthropathy
 History of ongoing infectious disease pathology, including human immunodeﬁciency virus (HIV)
and hepatitis B or C
 Participated in a study of an experimental drug or medical device within 30 days of study entryAppendix B. Outcomes of subjective functional outcomes and
pain questionnaireSummary of subjective functional results
Visit TissueGene-C Placebo
LS mean LS mean LS mea
KOOS subscale symptom
Week 4 6.9 7.7 0.7
Week 12 13.5 8.4 5.2
Week 24 10.5 13.2 2.7
Week 52 11.8 13.8 2.0
Overall 10.7 10.6 0.1
KOOS subscale pain
Week 4 12.7 14.8 2.1
Week 12 21.8 14.9 6.9
Week 24 20.7 19.1 1.5
Week 52 25 15.7 9.4
Overall 20 16.1 3.9
KOOS subscale ADL
Week 4 12.2 13.6 1.4
Week 12 20 13.5 6.4
Week 24 18.3 17.5 0.9
Week 52 22.1 16.2 5.9
Overall 18.1 15.2 3.0
KOOS subscale QOL
Week 4 14.8 13.9 0.9
Week 12 21.8 15.9 5.9
Week 24 17.8 19.9 2.1
Week 52 24.3 21.1 3.2
Overall 19.7 17.7 2.0
KOOS subscale sport
Week 4 13 13.2 0.3
Week 12 21.2 12 9.2
Week 24 18.2 21.1 2.9
Week 52 24.8 16.9 7.9
Overall 19.3 15.8 3.5
Lysholm scores
Week 4 14.6 11.2 3.4
Week 12 19.8 15.8 4.0
Week 24 16.6 17.9 1.3
Week 52 21.3 13.2 8.1
Overall 18.1 14.5 3.6
Lower extremity functional score
Week 4 9.8 10.9 5.8
Week 12 15.7 12.5 13.8
Week 24 14.4 15.6 7.7
Week 52 16.7 13.5 13.1
Overall 14.2 13.1 10.195% CI of LS mean difference P-value
n difference
6.5e5.0 0.8
0.8e11.1 0.087
8.6e3.3 0.374
8.3e4.2 0.524
5.0e4.8 0.98
10.5e6.3 0.621
1.6e21.8 0.111
7.1e10.2 0.729
0.4e18.4 0.042
3.6e11.5 0.304
9.3e6.5 0.723
1.6e9.5 0.116
7.3e9.0 0.833
2.6e14.5 0.172
4.1e10.0 0.405
8.9e10.8 0.849
4.1e15.8 0.846
12.2e8.1 0.686
7.6e13.9 0.559
6.7ee13.9 0.65
12.2e11.7 0.964
2.9e21.3 0.134
15.2e9.4 0.644
5.2e21.0 0.238
7.3e14.2 0.522
4.9e11.7 0.422
4.4e12.5 0.349
9.8e7.2 0.765
0.7e17.0 0.072
4.0e11.1 0.352
16.7e5.2 0.774
25.0e2.6 0.381
19.0e3.7 0.745
25.1e1.1 0.427
19.4e0.7 0.755
Summary of pain questionnaire
Visit TissueGene-C Placebo 95% CI of LS mean difference P-value
Mean Mean Mean difference
Severity of pain
Week 4 0.72 0.41 0.31 0.84e0.22 0.2222
Week 12 0.91 0.42 0.49 0.90e0.08 0.0184
Week 24 0.6 0.52 0.18 0.63e0.34 0.8260
Week 52 8.6 0.30 0.56 1.08e0.04 0.0399
Frequency of pain
Week 4 0.40 0.37 0.03 0.52e0.46 0.694
Week 12 1.0 0.71 0.29 0.87e0.29 0.286
Week 24 0.74 0.3 0.34 0.95e0.07 0.105
Week 52 1.14 0.35 0.79 1.43e0.15 0.025
Time since knee pain of pain questionnaire
Week 4 0.17 0.26 0.09 0.61e0.79 0.963
Week 12 0.34 0.04 0.3 1e0.24 0.589
Week 24 0.09 0.04 0.15 0.78e0.52 0.34
Week 52 0.03 0.11 0.14 0.98e0.84 0.532
Speed of onset pain questionnaire
Week 4 0.05 0.19 0.24 0.21e0.69 0.255
Week 12 0.12 0.14 0.02 0.48e0.52 0.856
Week 24 0.02 0.14 0.12 0.38e0.62 0.838
Week 52 0.17 0.16 0.33 0.25e0.91 0.191
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